Amerikanische Gesellschaft für Hirudotherapie

Autorità Sanitaria — Repubblica di San Marino

San Marino AS · San Marino · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

San Marino's Health Authority (Istituto per la Sicurezza Sociale) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate, with significant reliance on Italian / EU authorisations.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
San Marino
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • San Marino Legge sul Servizio Sanitario (Legge n. 42 del 22 dicembre 1955, as amended)
  • Operational reliance on Italian AIFA / EU EMA authorisations for medicinal products in practice

Prescriber Requirements

  • San Marino Ordine dei Medici–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Italian-language labelling per local convention; standard cold-chain conditions. Products typically enter via Italian customs and distribution channels.

Import/Export Rules

San Marino Servizio Veterinario clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana. Italian customs cooperation is the practical norm.

Reimbursement Context

Istituto per la Sicurezza Sociale (ISS) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; San Marino's small jurisdiction relies heavily on Italian AIFA authorisations in practice; whether the national legal framework would treat live-organism medical devices distinctly from this de-facto reliance has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.